| Previous Close | 15.10 |
| Open | 15.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 15.00 - 15.80 |
| 52 Week Range | 14.90 - 39.99 |
| Volume | 501,586 |
| Avg. Volume | 529,473 |
| Market Cap | 582.66M |
| Beta | 1.87 |
| PE Ratio (TTM) | -211.49 |
| EPS (TTM) | -0.07 |
| Earnings Date | Aug 23, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.17 |
Capital Cube•4 days agoLannett Co., Inc. – Value Analysis (NYSE:LCI) : August 15, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Lannett Co., Inc. a score of 41. Our analysis is based on comparing Lannett Co., Inc. with the following peers – Impax Laboratories, Inc., Pfizer Inc., Johnson & Johnson, Mylan N.V., GlaxoSmithKline plc Sponsored ADR, Akorn, Inc., Abbott Laboratories and Novartis AG Sponsored ADR (IPXL-US, PFE-US, JNJ-US, ... Read more (Read more...)
- PR Newswire•11 days ago
Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook
"While our industry is currently facing challenges, Lannett is strong and we have put in place a number of initiatives to position the company for long-term growth," said Arthur Bedrosian, chief executive officer of Lannett. "Approximately 80% of our marketed products continue to be in the top three in terms of market share and we are on track to submit a New Drug Application for our proprietary C-Topical product shortly. In addition, we are expanding our pain management capabilities to include the development of innovative Active Pharmaceutical Ingredients (APIs) for the treatment of pain and addiction, as well as the sale of APIs to compounding pharmacies. And, finally, our plans include entry into the veterinary pharmaceutical market.
- Motley Fool•12 days ago
3 Stocks Hitting 52-Week Lows: Time to Go Bargain Shopping?
Endologix, Lannett, and Teva stocks are sinking while the overall market is rising. Are they bargains or busts?
